Duration of intravenous antibiotic therapy for children with acute osteomyelitis or septic arthritis: a feasibility study

Abstract

Declared competing interests of authors: Saul N Faust was UK chief investigator and University Hospital Southampton NHS Foundation Trust principal investigator for a Cubist-sponsored clinical trial of daptomycin against standard of care antibiotic therapy in paediatric osteomyelitis. All funds were paid into accounts within the NHS trust or university and not paid as personal fees. He reports consultancy fees for advisory board participation paid into accounts within the NHS trust or university (not personal fees) from vaccine manufacturers and antimicrobial agent manufacturers, including AstraZeneca, Cubist, Merck, GlaxoSmithKline (GSK) and Pfizer, outside the submitted work. He acts as principal investigator for clinical trials and other studies conducted on behalf of University Hospital Southampton NHS Foundation Trust/ University of Southampton that are sponsored by vaccine manufacturers and antimicrobial agents, and has participated in advisory boards for vaccine manufacturers. Adam Finn reports grants and personal fees from Sanofi Pasteur MSD Ltd (SPMSD), and grants and personal fees from GSK, outside the submitted work. In addition, prior to October 2014, the University of Bristol and University Hospitals Bristol NHS Foundation Trust received funding for research conducted by Adam Finn and for consultancy and lectures from Pfizer, GSK, SPMSD and Novartis, who manufacture licensed and developmental meningococcal vaccines. Stuart C Clarke acts as principal investigator for clinical trials and other studies conducted on behalf of University Hospital Southampton NHS Foundation Trust/University of Southampton that are sponsored by vaccine manufacturers but receive no personal payments from them. He has participated in advisory boards for vaccine manufacturers and has received financial assistance from vaccine manufacturers to attend conferences, but receives no personal payments for this work. All grants and honoraria are paid into accounts within the respective NHS trusts or universities. Jethro Herberg reports that he was an investigator for a Cubist-sponsored clinical trial of daptomycin against standard of care antibiotic therapy in paediatric osteomyelitis; he received no personal payments. Andrew Riordan reports that the trust, but not he, has received funding for research sponsored by vaccine manufacturers and antimicrobial agents. He was lead editor for an e-learning package on meningitis produced by the Royal College of Paediatric and Child Health, funded by an unrestricted grant from Novartis Vaccines. Marieke Emonts was Newcastle upon Tyne Hospitals Foundation Trust's principal investigator for a Cubist-sponsored clinical trial of daptomycin against standard of care antibiotic therapy in paediatric osteomyelitis. All grants and honoraria are paid into accounts within the NHS trust or university; she received no personal payment of any kind. Marieke Emonts reports acting as site principle investigator on behalf of the Newcastle upon Tyne Hospitals Foundation Trust/Newcastle University for clinical tr...

Bone and joint infections in Oxford: a 10-year retrospective review

“…We showed that SA affects younger children more commonly than OM. S. aureus was the single most common causative agent of both OM and SA, which is consistent with a recent national cohort study 4. We found no clear difference between length of intravenous therapy and outcome.…”

Short postsurgical antibiotic therapy for spinal infections: protocol of prospective, randomized, unblinded, noninferiority trials (SASI trials)

“…There are also studies with less than 6 weeks of total antimicrobial therapy, especially in the pediatric literature on hematogenous osteomyelitis. In this particular setting, a 3-week antibiotic course appears to be sufficient, as highlighted by many authors [29][30][31][32]. Among adults, 38 case series with antibiotic treatment durations of 3-4 weeks, including 5 to 36 patients each, revealed cure rates of approximately 80% according to a review published in 2005 [33].…”

Short post-surgical antibiotic therapy in spine infections - prospective, randomized, unblinded, non-inferiority trials (SASI Trials)

“…There are also studies with less than six weeks of total antimicrobial therapy, especially in the pediatric literature for hematogenous osteomyelitis. In this particular setting, a three-week antibiotic course appears to be sufficient as highlighted by many authors [31][32][33][34]. For adults, 38 case series with antibiotic treatment durations of 3 to 4 weeks, including 5 to 36 patients each, revealed cure rates of approximately 80% according to a review published in 2005 [35].…”